PAINREFORM LTD. (PRFK), registered on NASDAQ, is a clinical-stage specialty pharmaceutical company focused on the research and development of innovative therapies designed to reduce post-surgical pain. The company's headquarters is located in Herzeliya, Israel.
Driven by a commitment to improving quality of life for patients undergoing surgery, PAINREFORM employs a unique drug delivery system to optimise the delivery and effectiveness of drugs used to lessen postoperative pain. The company's aim is to significantly advance the profile of existing drugs to lengthen the duration of pain relief, decrease adverse events, and reduce the necessity for follow-up care like physiotherapy.
PAINREFORM’s key product embraces a patented, extended-release, drug-delivery system that aims to provide safe and effective postoperative pain relief which reduces the requirement for systemic analgesics. Earlier formulations of postoperative pain medications have relied heavily on opioids, which commonly cause dependency and other serious side effects. Instead, PAINREFORM focuses on improving existing non-opioid drugs.
The lead product candidate of the company is PRF-110, an extended-release version of local anaesthetic ropivacaine. PRF-110 is unique in that it extends the release of pain medication over a period of several days, resulting in a potentially marked decrease in patient discomfort and a reduction in the overall need for supplemental pain medication after surgery.
PAINREFORM was founded in 2007 and has been publicly traded since 2020. The company continues to make substantial strides in its field by continually investing in clinical research and trials. Its management and advisory team is composed of seasoned professionals who bring a wealth of experience from various disciplines, including pharmaceutical development, financial management, legal, and regulatory.
While facing challenges like any other biotechnology company, particularly during the research and development phases where success is never guaranteed, PAINREFORM stays committed to its mission of improving post-surgical pain management methods.
The company represents a significant contributor to the change in narrative surrounding pain management within the health industry, reducing the reliance on opioids and focusing on innovative, safer, and more effective pain relief solutions.
In a nutshell, PAINREFORM LTD (PRFX) continues to showcase significant potential in the transformation of pain management practices. It leverages focusing on enhancing the patient healing journey while reducing the possibility of adverse drug effects and dependency, hence, reinventing the approach towards post-operative pain management.